Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tobacco Investment Means E-Cigarette Growth, But Drug Path Raises Questions

This article was originally published in The Tan Sheet

Executive Summary

Stakeholders discussed electronic cigarettes at an FDA public hearing on smoking cessation, reflecting big tobacco’s buy-in to the market. Firms appear to have a choice between remaining in tobacco’s regulatory space, or following the costly, potentially unclear route to an NDA.

Advertisement

Related Content

NRT Harm Reduction Indications Need Fast-Track Evaluation – Experts
E-Cigarette Firm Targets Harm Reduction In Therapeutic Claim
Smoking Cessation Claims For E-Cigarettes Draw FDA Warnings

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106155

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel